<html><head><link rel="stylesheet" type="text/css" href="css.css"></head><h1 id="artitle">The Snake-Oil Salesmen of the Senate<br></h1><p id="artcont">There is no evidence that hydroxychloroquine helps Covid-19 patients. So why is Congress still holding hearings on it? By Ashish Jha Dr. Jha, the dean of the Brown University School of Public Health, testified at a Senate hearing last week about hydroxychloroquine. There was a super-spreader event last week in the United States Senate. It wasn’t the coronavirus, however, that was spreading, but misinformation. The Senate Homeland Security and Governmental Affairs Committee held a hearing about early treatment for Covid-19. Yet instead of a robust discussion about promising emerging therapies or what Congress might do to accelerate such treatments, the conversation was all about the malaria drug hydroxychloroquine. That’s right. Almost nine months into the pandemic, during a surge, with 1,500 daily deaths, senators saw fit to rehash a medical dead end. Trial after trial has found no evidence that hydroxychloroquine improves outcomes for Covid-19 patients; some studies have found that it causes more harm than good. 